BIA

Generic Name: BIA

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀F_₃N_₃O_₅

Unique Ingredient Identifier: X6H65DT067

Clinical Trials

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067
Drug: Sinemet® 100/25 mg

First Posted Date: 2012-02-15

Last Posted Date: 2015-12-22

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 18

Registration Number: NCT01533077

Locations: 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067
Drug: Rasagiline

First Posted Date: 2012-02-14

Last Posted Date: 2015-08-20

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 25

Registration Number: NCT01532141

Locations: 🇫🇷
BIOTRIAL, Rennes, France

Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067
Drug: Placebo
Drug: moxifloxacin

First Posted Date: 2012-02-14

Last Posted Date: 2012-06-21

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 64

Registration Number: NCT01532115

Locations: 🇫🇷
Biotrial, 7-9 rue Jean-Louis Bertrand, Rennes, France

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: rasagiline
Drug: BIA 9-1067

First Posted Date: 2012-02-14

Last Posted Date: 2015-08-20

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 24

Registration Number: NCT01532128

Locations: 🇫🇷
BIOTRIAL, Rennes, France

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067
Drug: Placebo

First Posted Date: 2012-01-30

Last Posted Date: 2016-06-20

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 105

Registration Number: NCT01520987

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Honolulu, Hawaii, United States

A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067
Drug: Placebo

First Posted Date: 2012-01-30

Last Posted Date: 2015-01-08

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 64

Registration Number: NCT01520727

Locations: 🇫🇷
BIOTRIAL, Rennes, France

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067 5 mg
Drug: Entacapone
Drug: Placebo
Drug: BIA 9-1067 30 mg
Drug: levodopa/carbidopa
Drug: BIA 9-1067 15 mg

First Posted Date: 2012-01-26

Last Posted Date: 2015-08-20

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 82

Registration Number: NCT01519284

Locations: 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal

Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: BIA 9-1067

First Posted Date: 2012-01-24

Last Posted Date: 2015-01-09

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 4

Registration Number: NCT01515891

Locations: 🇨🇭
Covance Basel Research Unit AG (formerly Swiss Pharma Contract Ltd), Allschwil, Base, Switzerland

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Phase 3

Completed

Conditions: Parkinson's Disease

Interventions: Drug: BIA 9-1067
Drug: Placebo
Drug: Levodopa
Drug: Carbidopa
Drug: Benserazide

First Posted Date: 2010-10-25

Last Posted Date: 2015-10-19

Lead Sponsor: Bial - Portela C S.A.

Target Recruit Count: 427

Registration Number: NCT01227655

Locations: 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy